Authors: Blanchette, Christopher M.¹; Joshi, Ashish V.²; Szpalski, Marek³; Gunzburg, Robert⁴; Du Bois, Marc⁵; Donceel, Peter⁶; Saunders, William B.⁷

Source: Current Medical Research and Opinion, Volume 23, Number 11, November 2007 , pp. 2793-2804(12)

Publisher: Informa Healthcare

Abstract:

Objective: This study assessed utilization and cost of allogeneic blood transfusion (ABT) associated with spinal surgery in the United States (US) and Belgium.

Methods: A retrospective cohort of 292 864 spinal surgery inpatients in US hospitals was pooled with a cohort of 27 952 inpatients who had similar procedures in Belgian hospitals. Utilization and cost data were derived from hospital accounting systems. Costs were converted to US dollars. Descriptive and multivariate statistics were used to describe the factors associated with the use and cost of ABT. Missing data, confounding, and variable measurement error were addressed using standard approaches for observational studies.

Results: US hospitalizations cost $12 044 (SD = 15 920) over 3.6 days compared to $4010 (SD = 3586) over 10.3 days in Belgium. Low molecular weight heparin was used by 78% of Belgian patients and 4% of US patients. Red blood cell utilization occurred in approximately 7% of patients from both countries; however US patients received 6 units compared to 3 units by Belgian patients. US patients spent 3.5 (p < 0.0001) less days in hospital, 1.0 (p < 0.0001) more days in an intensive care unit, used 64% more allogeneic blood (OR = 1.64, 95% CI 1.53-1.75), and incurred $13 647 (p < 0.0001) more per hospitalization than Belgian patients.

Conclusions: US patients used more blood products, had shorter hospital stays, and incurred greater costs than Belgian patients. Specialists as attending physicians were associated with lower utilization of ABT; this may be an administrative change that hospitals can implement to reduce utilization and costs.

Keywords: ALLOGENEIC; COST; HOSPITAL; TRANSFUSION; UTILIZATION

Document Type: Research article

DOI: http://dx.doi.org/10.1185/030079907X233421

Affiliations: 1: Center for Pharmacoeconomic and Outcomes Research, Lovelace Respiratory Research Institute, Albuquerque, NM, USA 2: Novo Nordisk, Princeton, NJ, USA 3: IRIS South Teaching Hospitals, Free University of Brussels, Brussels, Belgium 4: Eeuwfeest Kliniek, Antwerp, Belgium 5: Christelijke Mutualiteit, Brussels, Belgium; Department of Occupational, Environmental and Insurance Medicine, Katholieke Universiteit Leuven, Belgium 6: Department of Occupational, Environmental and Insurance Medicine, Katholieke Universiteit Leuven, Belgium 7: Premier, Inc., Charlotte, NC, USA

Publication date: 2007-11-01

More about this publication?

• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• General Information
• Journal Information
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General)
• By this author: Blanchette, Christopher M. ;  Joshi, Ashish V. ;  Szpalski, Marek ;  Gunzburg, Robert ;  Du Bois, Marc ;  Donceel, Peter ;  Saunders, William B.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers